COVID-19 (corona virus disease) is a respiratory illness that is severe and potentially fatal. It can cause mortality in severe cases due to alveolar collapse. HCQ could be effectively used in the treatment of SARS-CoV pneumonia. However, the major problems of oral treatment with HCQ can cause possible severe side effects and toxicity; hepatic first-pass metabolism and drug accumulation in liver. Inhalable HCQ micro-particles pass through airway & prevent replication of virus effectively & surfactants maintain alveolar capacity. Administration of formulation using an autohaler (Inhaler) produces a long duration of action in the lungs and further absorption in systemic circulation, avoiding first-pass metabolism. In turn, inhalable HCQ microparticles could be an important tool for the management of acute respiratory distress syndrome (ARDS) in COVID as well as in the emergency care clinical team.
The Project Title and initial development has been patented.
The team has approx of 150 indexed publications and 15 other patents together with cumulative h Index approx 35, 6 Books, Cumulative Research Gate score 60.
Won Newgen IEDC prototyping grant of up to 2.5 Lac through NOVATE 2020
Granted a Patent with the application number – 202011025625
Ms. Rupanshi Grover
Email – firstname.lastname@example.org
Mobile – 9855348586